Expert consensus on perioperative treatment for non-small cell lung cancer

Jianchun Duan; Fengwei Tan; Nan Bi; Chun Chen; Ke Neng Chen; Ying Cheng; Qian Chu; Di Ge; Jie Hu; Yunchao Huang; Tao Jiang; Hao Long; You Lu; Meiqi Shi; Jialei Wang; Qiming Wang; Fan Yang; Nong Yang; Yu Yao; Jianming Ying; Caicun Zhou; Qing Zhou; Qinghua Zhou; Stefano Bongiolatti; Alessandro Brunelli; Alfonso Fiorelli; Elisa Gobbini; Cesare Gridelli; Thomas John; Jae Jun Kim; Steven H. Lin; Giulio Metro; Fabrizio Minervini; Nuria M. Novoa; Dwight H. Owen; Maria Rodriguez; Ichiro Sakanoue; Marco Scarci; Kenichi Suda; Fabrizio Tabbò; Terence Chi Chun Tam; Masanori Tsuchida; Junji Uchino; Luca Voltolini; Jie Wang; Shugeng Gao

doi:10.21037/tlcr-22-527

Expert consensus on perioperative treatment for non-small cell lung cancer

Jianchun Duan, Fengwei Tan, Nan Bi, Chun Chen, Ke Neng Chen, Ying Cheng, Qian Chu, Di Ge, Jie Hu, Yunchao Huang, Tao Jiang, Hao Long, You Lu, Meiqi Shi, Jialei Wang, Qiming Wang, Fan Yang, Nong Yang, Yu Yao, Jianming YingCaicun Zhou, Qing Zhou, Qinghua Zhou, Stefano Bongiolatti, Alessandro Brunelli, Alfonso Fiorelli, Elisa Gobbini, Cesare Gridelli, Thomas John, Jae Jun Kim, Steven H. Lin, Giulio Metro, Fabrizio Minervini, Nuria M. Novoa, Dwight H. Owen, Maria Rodriguez, Ichiro Sakanoue, Marco Scarci, Kenichi Suda, Fabrizio Tabbò, Terence Chi Chun Tam, Masanori Tsuchida, Junji Uchino, Luca Voltolini, Jie Wang, Shugeng Gao

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Non-small cell lung cancer (NSCLC) accounts for 85% of all newly diagnosed lung cancer cases. Among patients with NSCLC, about 20% are diagnosed with stage I and II, and 30% with stage III diseases (1). In recent years, the popularity of low-dose computed tomography (CT) screening for thoracic disease has resulted in a higher proportion of early-stage NSCLC cases being diagnosed. The mainstay of treatment for stages I–IIIA NSCLC is radical surgery coupled with neoadjuvant or adjuvant therapy in the appropriate setting (2). In patients with completely resected NSCLC, postoperative adjuvant chemotherapy has been associated with better overall survival (OS) in patients with early-stage disease. However, even for the patients with stage I NSCLC, the 5-year lung cancer-specific mortality rate after radical resection has remained unsatisfactory (3).

Original language	English (US)
Pages (from-to)	1247-1267
Number of pages	21
Journal	Translational Lung Cancer Research
Volume	11
Issue number	7
DOIs	https://doi.org/10.21037/tlcr-22-527
State	Published - Jul 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.21037/tlcr-22-527

Cite this

Duan, J., Tan, F., Bi, N., Chen, C., Chen, K. N., Cheng, Y., Chu, Q., Ge, D., Hu, J., Huang, Y., Jiang, T., Long, H., Lu, Y., Shi, M., Wang, J., Wang, Q., Yang, F., Yang, N., Yao, Y., ... Gao, S. (2022). Expert consensus on perioperative treatment for non-small cell lung cancer. Translational Lung Cancer Research, 11(7), 1247-1267. https://doi.org/10.21037/tlcr-22-527

Duan, J, Tan, F, Bi, N, Chen, C, Chen, KN, Cheng, Y, Chu, Q, Ge, D, Hu, J, Huang, Y, Jiang, T, Long, H, Lu, Y, Shi, M, Wang, J, Wang, Q, Yang, F, Yang, N, Yao, Y, Ying, J, Zhou, C, Zhou, Q, Zhou, Q, Bongiolatti, S, Brunelli, A, Fiorelli, A, Gobbini, E, Gridelli, C, John, T, Kim, JJ, Lin, SH, Metro, G, Minervini, F, Novoa, NM, Owen, DH, Rodriguez, M, Sakanoue, I, Scarci, M, Suda, K, Tabbò, F, Chun Tam, TC, Tsuchida, M, Uchino, J, Voltolini, L, Wang, J & Gao, S 2022, 'Expert consensus on perioperative treatment for non-small cell lung cancer', Translational Lung Cancer Research, vol. 11, no. 7, pp. 1247-1267. https://doi.org/10.21037/tlcr-22-527

@article{ae864ae51312473cbe111f3fdb0adad9,

title = "Expert consensus on perioperative treatment for non-small cell lung cancer",

abstract = "Non-small cell lung cancer (NSCLC) accounts for 85% of all newly diagnosed lung cancer cases. Among patients with NSCLC, about 20% are diagnosed with stage I and II, and 30% with stage III diseases (1). In recent years, the popularity of low-dose computed tomography (CT) screening for thoracic disease has resulted in a higher proportion of early-stage NSCLC cases being diagnosed. The mainstay of treatment for stages I–IIIA NSCLC is radical surgery coupled with neoadjuvant or adjuvant therapy in the appropriate setting (2). In patients with completely resected NSCLC, postoperative adjuvant chemotherapy has been associated with better overall survival (OS) in patients with early-stage disease. However, even for the patients with stage I NSCLC, the 5-year lung cancer-specific mortality rate after radical resection has remained unsatisfactory (3).",

author = "Jianchun Duan and Fengwei Tan and Nan Bi and Chun Chen and Chen, {Ke Neng} and Ying Cheng and Qian Chu and Di Ge and Jie Hu and Yunchao Huang and Tao Jiang and Hao Long and You Lu and Meiqi Shi and Jialei Wang and Qiming Wang and Fan Yang and Nong Yang and Yu Yao and Jianming Ying and Caicun Zhou and Qing Zhou and Qinghua Zhou and Stefano Bongiolatti and Alessandro Brunelli and Alfonso Fiorelli and Elisa Gobbini and Cesare Gridelli and Thomas John and Kim, {Jae Jun} and Lin, {Steven H.} and Giulio Metro and Fabrizio Minervini and Novoa, {Nuria M.} and Owen, {Dwight H.} and Maria Rodriguez and Ichiro Sakanoue and Marco Scarci and Kenichi Suda and Fabrizio Tabb{\`o} and {Chun Tam}, {Terence Chi} and Masanori Tsuchida and Junji Uchino and Luca Voltolini and Jie Wang and Shugeng Gao",

year = "2022",

month = jul,

doi = "10.21037/tlcr-22-527",

language = "English (US)",

volume = "11",

pages = "1247--1267",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

publisher = "Society for Translational Medicine (STM)",

number = "7",

}

TY - JOUR

T1 - Expert consensus on perioperative treatment for non-small cell lung cancer

AU - Duan, Jianchun

AU - Tan, Fengwei

AU - Bi, Nan

AU - Chen, Chun

AU - Chen, Ke Neng

AU - Cheng, Ying

AU - Chu, Qian

AU - Ge, Di

AU - Hu, Jie

AU - Huang, Yunchao

AU - Jiang, Tao

AU - Long, Hao

AU - Lu, You

AU - Shi, Meiqi

AU - Wang, Jialei

AU - Wang, Qiming

AU - Yang, Fan

AU - Yang, Nong

AU - Yao, Yu

AU - Ying, Jianming

AU - Zhou, Caicun

AU - Zhou, Qing

AU - Zhou, Qinghua

AU - Bongiolatti, Stefano

AU - Brunelli, Alessandro

AU - Fiorelli, Alfonso

AU - Gobbini, Elisa

AU - Gridelli, Cesare

AU - John, Thomas

AU - Kim, Jae Jun

AU - Lin, Steven H.

AU - Metro, Giulio

AU - Minervini, Fabrizio

AU - Novoa, Nuria M.

AU - Owen, Dwight H.

AU - Rodriguez, Maria

AU - Sakanoue, Ichiro

AU - Scarci, Marco

AU - Suda, Kenichi

AU - Tabbò, Fabrizio

AU - Chun Tam, Terence Chi

AU - Tsuchida, Masanori

AU - Uchino, Junji

AU - Voltolini, Luca

AU - Wang, Jie

AU - Gao, Shugeng

PY - 2022/7

Y1 - 2022/7

N2 - Non-small cell lung cancer (NSCLC) accounts for 85% of all newly diagnosed lung cancer cases. Among patients with NSCLC, about 20% are diagnosed with stage I and II, and 30% with stage III diseases (1). In recent years, the popularity of low-dose computed tomography (CT) screening for thoracic disease has resulted in a higher proportion of early-stage NSCLC cases being diagnosed. The mainstay of treatment for stages I–IIIA NSCLC is radical surgery coupled with neoadjuvant or adjuvant therapy in the appropriate setting (2). In patients with completely resected NSCLC, postoperative adjuvant chemotherapy has been associated with better overall survival (OS) in patients with early-stage disease. However, even for the patients with stage I NSCLC, the 5-year lung cancer-specific mortality rate after radical resection has remained unsatisfactory (3).

AB - Non-small cell lung cancer (NSCLC) accounts for 85% of all newly diagnosed lung cancer cases. Among patients with NSCLC, about 20% are diagnosed with stage I and II, and 30% with stage III diseases (1). In recent years, the popularity of low-dose computed tomography (CT) screening for thoracic disease has resulted in a higher proportion of early-stage NSCLC cases being diagnosed. The mainstay of treatment for stages I–IIIA NSCLC is radical surgery coupled with neoadjuvant or adjuvant therapy in the appropriate setting (2). In patients with completely resected NSCLC, postoperative adjuvant chemotherapy has been associated with better overall survival (OS) in patients with early-stage disease. However, even for the patients with stage I NSCLC, the 5-year lung cancer-specific mortality rate after radical resection has remained unsatisfactory (3).

UR - http://www.scopus.com/inward/record.url?scp=85135342113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135342113&partnerID=8YFLogxK

U2 - 10.21037/tlcr-22-527

DO - 10.21037/tlcr-22-527

M3 - Article

C2 - 35958323

AN - SCOPUS:85135342113

SN - 2218-6751

VL - 11

SP - 1247

EP - 1267

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

IS - 7

ER -

Expert consensus on perioperative treatment for non-small cell lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this